Furthermore, this mutation occurs during tumor formation in the earliest stages of tumor development; thus, according to WHO 2021 glioma classifications, the IDH mutation status should be examined when classifying glioblastoma and astrocytomas/oligodendrogliomas (Table 1). Here, IDH2 is linked to central nervous system cancer.